title: CCR5 delta32 deletion and response to highly active antiretroviral therapy in HIV-1-infected patients.
authors: INSERM U292, Department of Epidemiology, Bicêtre Hospital, Le Kremlin-Bicêtre, France.
authors: S
authors: S
authors: Guérin
authors: L
authors: L
authors: Meyer
authors: I
authors: I
authors: Theodorou
authors: F
authors: F
authors: Boufassa
authors: M
authors: M
authors: Magierowska
authors: C
authors: C
authors: Goujard
authors: C
authors: C
authors: Rouzioux
authors: P
authors: P
authors: Debré
authors: J F
authors: JF
authors: Delfraissy
mesh_terms: D019380:Anti-HIV Agents / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active; D015331:Cohort Studies; D005500:Follow-Up Studies; D005838:Genotype; D015658:HIV Infections / Q000188:drug therapy* / Q000235:genetics*; D006801:Humans; D016015:Logistic Models; D016017:Odds Ratio; D019713:Receptors, CCR5 / Q000235:genetics* / Q000378:metabolism*; D017384:Sequence Deletion / Q000235:genetics*; D016896:Treatment Outcome
chemical_list: D019380:Anti-HIV Agents; D019713:Receptors, CCR5